Richard Kim

Richard Kim was appointed Chief Commercial Officer in February 2021. Prior to joining Avadel, he served as the President of US Commercial & Strategic Marketing at Intercept Pharmaceuticals, Inc. During his time there, he helped to successfully launch OCALIVA™ (obeticholic acid), the first new treatment in nearly 20 years for the orphan disease primary biliary cholangitis, and led the launch strategy for NASH. Before Intercept, Richard served as General Manager, Hepatitis C Worldwide Commercialization, at Bristol-Myers Squibb, where he led the successful worldwide launch of DAKLINZA™ (daclatasvir). Prior to this, he held several roles of increasing responsibility leading sales, operational, and strategic marketing teams at Bristol-Myers Squibb, including Vice President, SPRYCEL™ Brand Lead, Oncology Global Marketing; Vice President, US In-Line Oncology and Global Marketing; and Vice President, East Area Sales, Cardiovascular and Metabolics. Prior to his time at Bristol-Myers Squibb, Richard held a range of senior positions in the US, Canada, and Australia at Schering-Plough, which was acquired by Merck & Co., Inc. Richard received a bachelor's degree in chemistry from the University of Alberta.